Home > Blog > Orphan drug designations and orphan subsets podcast

1 min read

Podcast: Orphan Drug Designations and Orphan Subsets

Regulatory Consulting Regulatory Submissions

Sponsors developing drugs or biologics intended to prevent, diagnose, or treat a rare disease or condition should consider applying for the Orphan Drug Designation (ODD) program with the FDA. The FDA’s Orphan Drug Designation program is meant to encourage the development of therapies for rare diseases and provides incentives for orphan products including exemption from user fees, a potential for 7 years of market exclusivity, and tax credits for some clinical trials.

Listen to the full episode on Veristat’s Advancing Revolutionary Therapies (ART) Podcast to learn more about Orphan Drug Designation classification and the strategic use of orphan subsets in study design.

Learning Points

  • Orphan Drug Designation criteria
  • What makes a subgroup of a disease ‘inappropriate’ or ‘scientifically justified’ for orphan drug designation?
  • Scenario examples of how to determine a ‘scientifically justified' orphan subgroup.

LISTEN TO PODCAST

 

 Meet Veristat. Learn More. 

1 min read

Meet Veristat at PHUSE US Connect: Advancing Data-Driven Clinical Development

Mar 18, 2026  Veristat Events

🔬 Connecting with the Global Clinical Data and Biostatistics Community

Veristat is pleased to attend PHUSE US Connect...

2 min read

Veristat Live in China: March 12-20, 2026

Mar 10, 2026  Veristat Events

Meet Veristat at BIOCHINA & CMAC: Advancing Global Clinical Development

🔬 Connecting with the Global Biotech Community